PL2476435T3 - Peptydy immunogenne i ich zastosowanie w zaburzeniach immunologicznych - Google Patents

Peptydy immunogenne i ich zastosowanie w zaburzeniach immunologicznych

Info

Publication number
PL2476435T3
PL2476435T3 PL11187012T PL11187012T PL2476435T3 PL 2476435 T3 PL2476435 T3 PL 2476435T3 PL 11187012 T PL11187012 T PL 11187012T PL 11187012 T PL11187012 T PL 11187012T PL 2476435 T3 PL2476435 T3 PL 2476435T3
Authority
PL
Poland
Prior art keywords
immunogenic peptides
immunological disorders
immunological
disorders
immunogenic
Prior art date
Application number
PL11187012T
Other languages
English (en)
Inventor
Jean-Marie Saint-Remy
Original Assignee
Life Sciences Research Partners Vzw
Katholieke Universiteit Leuven
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0615966A external-priority patent/GB0615966D0/en
Priority claimed from GB0710081A external-priority patent/GB0710081D0/en
Priority claimed from GB0711403A external-priority patent/GB0711403D0/en
Application filed by Life Sciences Research Partners Vzw, Katholieke Universiteit Leuven filed Critical Life Sciences Research Partners Vzw
Publication of PL2476435T3 publication Critical patent/PL2476435T3/pl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4713—Autoimmune diseases, e.g. Insulin-dependent diabetes mellitus, multiple sclerosis, rheumathoid arthritis, systemic lupus erythematosus; Autoantigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0008—Antigens related to auto-immune diseases; Preparations to induce self-tolerance
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/35—Allergens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/20—Cellular immunotherapy characterised by the effect or the function of the cells
    • A61K40/22—Immunosuppressive or immunotolerising
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/416—Antigens related to auto-immune diseases; Preparations to induce self-tolerance
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/48—Allergens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/415—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from plants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/43504—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates
    • C07K14/43513—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates from arachnidae
    • C07K14/43531—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates from arachnidae from mites
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4717—Plasma globulins, lactoglobulin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/62—Insulins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/0004—Oxidoreductases (1.)
    • C12N9/0065—Oxidoreductases (1.) acting on hydrogen peroxide as acceptor (1.11)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/88—Lyases (4.)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/572—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 cytotoxic response
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y111/00—Oxidoreductases acting on a peroxide as acceptor (1.11)
    • C12Y111/01—Peroxidases (1.11.1)
    • C12Y111/01008—Iodide peroxidase (1.11.1.8)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y401/00—Carbon-carbon lyases (4.1)
    • C12Y401/01—Carboxy-lyases (4.1.1)
    • C12Y401/01015—Glutamate decarboxylase (4.1.1.15)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Wood Science & Technology (AREA)
  • Toxicology (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Cell Biology (AREA)
  • Insects & Arthropods (AREA)
  • General Engineering & Computer Science (AREA)
  • Rheumatology (AREA)
  • Mycology (AREA)
  • Virology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Rehabilitation Therapy (AREA)
PL11187012T 2006-08-11 2007-08-13 Peptydy immunogenne i ich zastosowanie w zaburzeniach immunologicznych PL2476435T3 (pl)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
GB0615966A GB0615966D0 (en) 2006-08-11 2006-08-11 Novel therapy for immune disorders
GB0710081A GB0710081D0 (en) 2007-05-25 2007-05-25 Novel cellular therapy for immune disorders
GB0711403A GB0711403D0 (en) 2007-06-13 2007-06-13 Therapy for immune disorders
EP07801643.3A EP2059256B1 (en) 2006-08-11 2007-08-13 Immunogenic peptides and their use in immune disorders
EP11187012.7A EP2476435B1 (en) 2006-08-11 2007-08-13 Immunogenic peptides and their use in immune disorders

Publications (1)

Publication Number Publication Date
PL2476435T3 true PL2476435T3 (pl) 2018-05-30

Family

ID=38626589

Family Applications (3)

Application Number Title Priority Date Filing Date
PL11187013T PL2476436T3 (pl) 2006-08-11 2007-08-13 Peptydy immunogenne i ich zastosowanie w zaburzeniach immunologicznych
PL07801643T PL2059256T3 (pl) 2006-08-11 2007-08-13 Immunogenne peptydy i ich zastosowanie w zaburzeniach immunologicznych
PL11187012T PL2476435T3 (pl) 2006-08-11 2007-08-13 Peptydy immunogenne i ich zastosowanie w zaburzeniach immunologicznych

Family Applications Before (2)

Application Number Title Priority Date Filing Date
PL11187013T PL2476436T3 (pl) 2006-08-11 2007-08-13 Peptydy immunogenne i ich zastosowanie w zaburzeniach immunologicznych
PL07801643T PL2059256T3 (pl) 2006-08-11 2007-08-13 Immunogenne peptydy i ich zastosowanie w zaburzeniach immunologicznych

Country Status (10)

Country Link
US (4) US9249202B2 (pl)
EP (4) EP2476435B1 (pl)
JP (2) JP5750600B2 (pl)
AU (1) AU2007283731B2 (pl)
CA (2) CA2926004A1 (pl)
DK (3) DK2059256T3 (pl)
ES (4) ES2657504T3 (pl)
PL (3) PL2476436T3 (pl)
PT (3) PT2059256T (pl)
WO (1) WO2008017517A1 (pl)

Families Citing this family (54)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK2059256T3 (en) 2006-08-11 2016-12-05 Life Sciences Res Partners Vzw Immunogenic peptides AND USE THEREOF FOR THE IMMUNE DISORDERS
US20140105980A1 (en) * 2012-10-11 2014-04-17 Uti Limited Partnership Methods and compositions for treating multiple sclerosis and related disorders
CN103272227B (zh) 2007-08-15 2014-12-10 切尔卡西亚有限公司 针对过敏原去敏化的肽
AU2009214038B2 (en) * 2008-02-14 2013-08-22 Katholieke Universiteit Leuven Elimination of immune responses to viral vectors
ES2626115T3 (es) 2008-02-14 2017-07-24 Life Sciences Research Partners Vzw Péptidos inmunogénicos y su uso en trasplante
AU2009214041A1 (en) 2008-02-14 2009-08-20 Katholieke Universiteit Leuven CD4+ T-cells with cytolytic properties
AU2009214042B2 (en) * 2008-02-14 2014-02-13 Katholieke Universiteit Leuven Immunotherapy targeting intracellular pathogens
AU2014259586B2 (en) * 2008-02-14 2017-01-05 Katholieke Universiteit Leuven CD4+ T-cells with cytolytic properties
EP3075391A1 (en) * 2008-02-14 2016-10-05 Life Sciences Research Partners VZW Strategies to prevent and/or treat immune responses to soluble allofactors
AU2009214039B2 (en) * 2008-02-14 2013-09-19 Katholieke Universiteit Leuven Immunogenic control of tumours and tumour cells
GB201002730D0 (en) * 2010-02-18 2010-04-07 Uni I Oslo Product
US9801927B2 (en) * 2010-03-29 2017-10-31 Centre National De La Recherche Scientifique-Cnrs Pharmaceutical compositions comprising a polypeptide comprising at least one CXXC motif and heterologous antigens and uses thereof
EP2378287A1 (en) * 2010-04-15 2011-10-19 TXCell New method for isolating Tr1 cells
US9511151B2 (en) 2010-11-12 2016-12-06 Uti Limited Partnership Compositions and methods for the prevention and treatment of cancer
CN103261218B (zh) * 2010-11-25 2020-08-14 Imnate责任有限公司 免疫原性肽在预防和/或治疗疾病中的应用
WO2013083140A1 (en) 2011-12-07 2013-06-13 N.V. Nutricia Beta-lactoglobulin peptides for treating cow's milk protein allergy
GB201201511D0 (en) * 2012-01-30 2012-03-14 Univ Leuven Kath Modified epitopes for boosting CD4+ T-cell responses
US10988516B2 (en) 2012-03-26 2021-04-27 Uti Limited Partnership Methods and compositions for treating inflammation
EP2844741A1 (en) 2012-04-30 2015-03-11 ImCyse SA Methods for induction of antigen-specific regulatory t cells
US9603948B2 (en) 2012-10-11 2017-03-28 Uti Limited Partnership Methods and compositions for treating multiple sclerosis and related disorders
CN105142653B (zh) * 2013-03-15 2019-11-15 阿肯色大学评议会 增强对肠病原体免疫应答的组合物和方法
GB201309469D0 (en) 2013-05-28 2013-07-10 Imcyse Sa Detection of CD4+ T lymphocytes
EP3065771B1 (en) 2013-11-04 2019-03-20 UTI Limited Partnership Methods and compositions for sustained immunotherapy
AU2014369866A1 (en) * 2013-12-23 2016-06-30 Alk-Abello A/S Peptide combinations and uses thereof in treating dust mite allergy
EP2982746A1 (en) * 2014-08-07 2016-02-10 TXCell Regulatory T cells with therapeutic potential
GB201418433D0 (en) * 2014-10-17 2014-12-03 Imcyse Sa Novel immunogenic peptides
CN107847582A (zh) 2015-05-06 2018-03-27 优迪有限合伙公司 用于持续疗法的纳米颗粒组合物
US10729791B2 (en) 2015-05-18 2020-08-04 Imcyse Sa Animal models for evaluating pharmaceutical compounds
WO2019113342A1 (en) 2017-12-07 2019-06-13 Sanford Burnham Prebys Medical Discovery Institute Compositions and methods for treating nervous system injuries
WO2017040976A1 (en) 2015-09-02 2017-03-09 Erkki Ruoslahti Compounds and compositions for targeting brain injuries and methods of use thereof
US11787849B2 (en) 2015-09-25 2023-10-17 Imcyse Sa Methods and compounds for eliminating immune responses to therapeutic agents
SG11201808710UA (en) 2016-04-19 2018-11-29 Imcyse Sa Novel immunogenic cd1d binding peptides
JP7122002B2 (ja) * 2017-03-01 2022-08-19 国立大学法人北海道大学 疾患モデル非ヒト動物の製造方法、疾患モデル非ヒト動物、該動物を用いた薬剤のスクリーニング方法及び疾患リスク判定方法
CU24596B1 (es) 2017-03-09 2022-05-11 Imcyse Sa Péptidos obtenidos a partir de insulina útiles en el tratamiento de diabetes
EP3388447A1 (en) 2017-04-14 2018-10-17 Imnate Sarl Methods to produce peptides, polypeptides or cells for modulating immunity
AU2018298422B2 (en) 2017-07-04 2023-04-06 CureVac SE Novel nucleic acid molecules
IL321714A (en) 2017-10-19 2025-08-01 CureVac SE Novel artificial nucleic acid molecules
AU2018374569B2 (en) 2017-11-29 2024-10-17 Uti Limited Partnership Methods of treating autoimmune disease
CN110317246B (zh) * 2018-03-28 2022-08-02 深圳市安群生物工程有限公司 人mog抗原表位肽、抗原、抗体、应用及化学发光试剂盒
US20210401976A1 (en) * 2018-11-12 2021-12-30 Imcyse Sa Immunogenic peptides with improved oxidoreductase motifs
TW202039534A (zh) 2018-12-14 2020-11-01 美商美國禮來大藥廠 KRAS變體mRNA分子
JP2022532409A (ja) * 2019-05-16 2022-07-14 アンシス・エスア 改変されたシステインを含む酸化還元酵素モチーフを有する免疫原性ペプチド
EP3756648A1 (en) * 2019-06-27 2020-12-30 Imnate Sarl Improved vaccine formulations
CN114746111A (zh) * 2019-11-27 2022-07-12 易姆赛斯股份公司 用于对糖尿病患者进行分层的方法
JP2023518446A (ja) * 2020-03-20 2023-05-01 モナッシュ ユニバーシティ ループスを処置するための組成物及び方法
EP4146254A1 (en) * 2020-05-06 2023-03-15 Imcyse SA Immunogenic peptides with extended oxidoreductase motifs
JP2023525079A (ja) 2020-05-06 2023-06-14 アンシス・エスア フマレート関連疾患の併用療法
JP2023525080A (ja) 2020-05-06 2023-06-14 アンシス・エスア 新たな酸化還元酵素モチーフを有する免疫原性ペプチド
AR122023A1 (es) 2020-05-06 2022-08-03 Imcyse Sa Péptidos y métodos para el tratamiento de esclerosis múltiple
EP3915575A1 (en) * 2020-05-29 2021-12-01 Imnate Sarl Vaccine formulations
EP4346883A1 (en) 2021-05-26 2024-04-10 Imcyse SA Methods of treating or preventing autoimmune diseases
MX2023014318A (es) 2021-06-01 2024-01-25 Imcyse Sa Metodos de tratamiento mejorados utilizando peptidos inmunogenicos.
AR126654A1 (es) 2021-06-29 2023-11-01 Imcyse Sa Péptidos y métodos para el tratamiento de neuromielitis óptica
WO2025088088A1 (en) 2023-10-27 2025-05-01 CureVac SE Rna composition for improving cell therapy

Family Cites Families (79)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4599231A (en) 1984-03-09 1986-07-08 Scripps Clinic And Research Foundation Synthetic hepatitis B virus vaccine including both T cell and B cell determinants
WO1985004103A1 (en) 1984-03-09 1985-09-26 Scripps Clinic And Research Foundation Synthetic hepatitis b virus vaccine including both t cell anc b cell determinants
US4886782A (en) * 1987-02-26 1989-12-12 The United States Of America As Represented By The Department Of Health And Human Services Malarial immunogen
US5433948A (en) 1990-02-13 1995-07-18 Thomas; Wayne R. Cloning and sequencing of allergens of dermatophagoides (house dust mite)
JPH06501260A (ja) 1990-09-27 1994-02-10 シンテロ　ヴァクシーン　ディベロップメント　ケービー ヒト免疫不全ウィルスに対する中和抗体の誘発とワクチン接種に用いられるペプチド
US5912170A (en) 1991-03-07 1999-06-15 The General Hospital Corporation Redirection of cellular immunity by protein-tyrosine kinase chimeras
EP0623168B1 (en) * 1991-10-16 2009-09-30 Merck Patent GmbH T cell epitopes of the major allergens from dermatophagoides (house dust mite)
US7252829B1 (en) 1998-06-17 2007-08-07 Idm Pharma, Inc. HLA binding peptides and their uses
US5589582A (en) 1992-10-27 1996-12-31 Biotransplant, Inc. Polynucleotides en coding porcine cytokines
US5633234A (en) 1993-01-22 1997-05-27 The Johns Hopkins University Lysosomal targeting of immunogens
DK0735893T3 (da) 1993-09-14 2009-03-09 Pharmexa Inc PAN DR-bindende peptider til styrkelse af immunsvaret
US5824315A (en) 1993-10-25 1998-10-20 Anergen, Inc. Binding affinity of antigenic peptides for MHC molecules
US8791237B2 (en) 1994-11-08 2014-07-29 The Trustees Of The University Of Pennsylvania Compositions and methods for treatment of non-hodgkins lymphoma
US7157089B1 (en) 1996-11-26 2007-01-02 Stressgen Biotechnologies Corporation Immune responses using compositions containing stress proteins
US6399383B1 (en) 1997-10-28 2002-06-04 Maxygen, Inc. Human papilloma virus vectors
NO315238B1 (no) 1998-05-08 2003-08-04 Gemvax As Peptider som stammer fra leserammeforskyvingsmutasjoner i TBF<beta>II- eller BAX-genet, og farmasöytiske sammensetninger inneholdende disse,nukleinsyresekvenser som koder for slike peptider, plasmider og virusvektoreromfattende slikenukleinsy
AR020102A1 (es) * 1998-07-30 2002-04-10 Ucb Sa Compuesto para la prevencion y/o tratamiento de la alergia; composicion farmaceutica, composicion cosmetica, composicion en forma de bebida, alimento y/oalimento para animales domesticos que lo comprende y uso de dicho compuesto o dicha composicion farmaceutica para la fabricacion de un alimento
US20030152581A1 (en) * 1998-07-30 2003-08-14 Jean-Marie Saint-Remy Compound and method for the prevention and/or the treatment of allergy
WO2000029008A2 (en) 1998-11-16 2000-05-25 Board Of Regents, The University Of Texas System Hiv-specific t-cell induction
US7780882B2 (en) 1999-02-22 2010-08-24 Georgetown University Simplified and improved method for preparing an antibody or an antibody fragment targeted immunoliposome for systemic administration of a therapeutic or diagnostic agent
US7157091B1 (en) * 1999-06-18 2007-01-02 Ludwig Institute For Cancer Research MAGE-A1 peptides presented by HLA class II molecules
EP1252309A2 (en) 2000-01-28 2002-10-30 THE GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented by the Secretary, Department of Health and Human Services Mhc class ii restricted t cell epitopes from the cancer antigen ny-eso-1
GB0006437D0 (en) * 2000-03-17 2000-05-10 Leuven Res & Dev Vzw Compounds for the modulation of allergen sensitivity by antigens sharing T cell epitopes with allergens
AU2001272491A1 (en) 2000-06-26 2002-01-08 Smithkline Beecham Biologicals (S.A.) Triple fusion proteins comprising ubiquitin fused between thioredoxin and a polypeptide of interest
US8318173B2 (en) * 2001-04-05 2012-11-27 The John Hopkins University Chimeric vaccines
US7049413B2 (en) 2001-05-18 2006-05-23 Ludwig Institute For Cancer Research MAGE-A3 peptides presented by HLA class II molecules
JP2004527263A (ja) 2001-05-30 2004-09-09 フォンダツィオーネ テレソン 免疫抑制活性を有するエクスビボ単離ｃｄ２５＋ｃｄ４＋ｔ細胞とその使用
IL160641A0 (en) 2001-10-03 2004-07-25 Unilever Plc Carbohydrate binding domain containing fusion proteins for delivery of therapeutic and other agents, and compositions containing them
AU2003215395A1 (en) 2002-02-21 2003-09-09 Apovia, Inc. STABILIZED HBc CHIMER PARTICLES HAVING MENINGOCCOCAL IMMUNOGENS
US20100183652A1 (en) 2002-02-21 2010-07-22 Mark Page STABILIZED HBc CHIMER PARTICLES AS THERAPEUTIC VACCINE FOR CHRONIC HEPATITIS
IL164281A0 (en) * 2002-04-01 2005-12-18 Euro Celtique Sa Epitope constructs comprising antigen presenting cell targeting mechanisms
WO2004018667A1 (ja) 2002-08-26 2004-03-04 Kirin Beer Kabushiki Kaisha ペプチド及びこれを含む医薬
EP1548032B9 (en) * 2002-09-12 2009-10-28 Oncotherapy Science, Inc. Kdr peptides and vaccines comprising the same
JP2004147649A (ja) 2002-10-11 2004-05-27 Kumamoto Technology & Industry Foundation 頭頚部癌の抗原
JP2003289887A (ja) * 2003-02-13 2003-10-14 Univ Harvard 免疫調節ペプチド
CA2520768A1 (en) 2003-03-28 2005-02-10 Idm Pharma, Inc. Methods of identifying optimal variants of peptide epitopes
US7651855B2 (en) * 2003-04-17 2010-01-26 The Trustees Of The University Of Pennsylvania Regulatory T cells and their use in immunotherapy and suppression of autoimmune responses
EP2481422A3 (en) 2003-09-03 2013-04-03 Dendritherapeutics, Inc. Multiplex vaccines
GB0324265D0 (en) * 2003-10-16 2003-11-19 Medical Res Council Peptide
WO2005042575A2 (en) 2003-10-30 2005-05-12 Pharmexa A/S Method for down-regulation of vegf
WO2006009920A2 (en) 2004-06-17 2006-01-26 Mannkind Corporation Epitope analogs
JP2008044848A (ja) * 2004-11-30 2008-02-28 Univ Kurume Ｈｌａ−ａ２４拘束性腫瘍抗原ペプチド
US8252893B2 (en) 2005-01-31 2012-08-28 Board Of Trustees Of The University Of Arkansas CD8 T cell epitopes in HPV 16 E6 and E7 proteins and uses thereof
WO2007027954A2 (en) 2005-08-30 2007-03-08 Children's Hospital & Research Center At Oakland Methods for identifying an epitope of a polypeptide, chlamydial antigenic polypeptides identified thereby, and methods of use thereof
US10183986B2 (en) 2005-12-15 2019-01-22 Industrial Technology Research Institute Trimeric collagen scaffold antibodies
GB0603081D0 (en) 2006-02-15 2006-03-29 Dynal Biotech Asa Oslo Method
FR2898275B1 (fr) 2006-03-10 2012-12-14 Genethon Cellules t regulatrices cd4+cd25+specifiques pour la greffe de cellules hematopoietiques et la tolerance immunitaire
WO2007135684A2 (en) 2006-05-22 2007-11-29 Hadasit Medical Research Services & Development Limited Method of treatment of anti-cd4 autoimmunity
DK2059256T3 (en) 2006-08-11 2016-12-05 Life Sciences Res Partners Vzw Immunogenic peptides AND USE THEREOF FOR THE IMMUNE DISORDERS
ES2602610T3 (es) 2007-05-31 2017-02-21 Medigene Ag Proteína estructural mutada de un parvovirus
EP2205252B1 (en) 2007-09-27 2017-04-05 The Board Of Trustees Of The University Of Arkansas Inhibition of dendritic cell-driven regulatory t cell activation and potentiation of tumor antigen-specific t cell responses by interleukin-15 and map kinase inhibitor
EP3075391A1 (en) 2008-02-14 2016-10-05 Life Sciences Research Partners VZW Strategies to prevent and/or treat immune responses to soluble allofactors
ES2626115T3 (es) 2008-02-14 2017-07-24 Life Sciences Research Partners Vzw Péptidos inmunogénicos y su uso en trasplante
AU2009214042B2 (en) 2008-02-14 2014-02-13 Katholieke Universiteit Leuven Immunotherapy targeting intracellular pathogens
AU2009214039B2 (en) 2008-02-14 2013-09-19 Katholieke Universiteit Leuven Immunogenic control of tumours and tumour cells
AU2009214041A1 (en) 2008-02-14 2009-08-20 Katholieke Universiteit Leuven CD4+ T-cells with cytolytic properties
AU2009214038B2 (en) 2008-02-14 2013-08-22 Katholieke Universiteit Leuven Elimination of immune responses to viral vectors
WO2009101201A2 (de) 2008-02-15 2009-08-20 Chemetall Gmbh Mischungen aus metallhydriden und ionischen flüssigkeiten und verwendungen solcher mischungen
EP2254592B1 (en) 2008-02-28 2019-06-05 Dako Denmark A/S Mhc multimers in borrelia diagnostics and disease
KR101022649B1 (ko) 2008-08-07 2011-03-22 삼성모바일디스플레이주식회사 헤테로고리 화합물 및 이를 이용한 유기 전계 발광 장치
US20110318380A1 (en) 2008-10-01 2011-12-29 Dako Denmark A/S MHC Multimers in Cancer Vaccines and Immune Monitoring
AU2010232512B2 (en) 2009-04-01 2013-07-18 University Of Miami Vaccine compositions and methods of use thereof
US9801927B2 (en) 2010-03-29 2017-10-31 Centre National De La Recherche Scientifique-Cnrs Pharmaceutical compositions comprising a polypeptide comprising at least one CXXC motif and heterologous antigens and uses thereof
CN103261218B (zh) 2010-11-25 2020-08-14 Imnate责任有限公司 免疫原性肽在预防和/或治疗疾病中的应用
GB201201511D0 (en) 2012-01-30 2012-03-14 Univ Leuven Kath Modified epitopes for boosting CD4+ T-cell responses
CN110075284A (zh) 2012-02-15 2019-08-02 洛桑聚合联合学院 红细胞结合性治疗剂
GB201309469D0 (en) 2013-05-28 2013-07-10 Imcyse Sa Detection of CD4+ T lymphocytes
GB201319160D0 (en) 2013-10-30 2013-12-11 Imcyse Sa Methods for induction of antigen-specific regulatory t cells
GB201418433D0 (en) 2014-10-17 2014-12-03 Imcyse Sa Novel immunogenic peptides
US10729791B2 (en) 2015-05-18 2020-08-04 Imcyse Sa Animal models for evaluating pharmaceutical compounds
US11787849B2 (en) 2015-09-25 2023-10-17 Imcyse Sa Methods and compounds for eliminating immune responses to therapeutic agents
SG11201808710UA (en) 2016-04-19 2018-11-29 Imcyse Sa Novel immunogenic cd1d binding peptides
CU24596B1 (es) 2017-03-09 2022-05-11 Imcyse Sa Péptidos obtenidos a partir de insulina útiles en el tratamiento de diabetes
US20210401976A1 (en) 2018-11-12 2021-12-30 Imcyse Sa Immunogenic peptides with improved oxidoreductase motifs
JP2022532409A (ja) 2019-05-16 2022-07-14 アンシス・エスア 改変されたシステインを含む酸化還元酵素モチーフを有する免疫原性ペプチド
JP2023525079A (ja) 2020-05-06 2023-06-14 アンシス・エスア フマレート関連疾患の併用療法
JP2023525080A (ja) 2020-05-06 2023-06-14 アンシス・エスア 新たな酸化還元酵素モチーフを有する免疫原性ペプチド
AR122023A1 (es) 2020-05-06 2022-08-03 Imcyse Sa Péptidos y métodos para el tratamiento de esclerosis múltiple
EP4146254A1 (en) 2020-05-06 2023-03-15 Imcyse SA Immunogenic peptides with extended oxidoreductase motifs

Also Published As

Publication number Publication date
US11718650B2 (en) 2023-08-08
PT2476436T (pt) 2018-02-23
US20160194367A1 (en) 2016-07-07
EP2476436B1 (en) 2017-11-29
US20200317742A1 (en) 2020-10-08
ES2657504T3 (es) 2018-03-05
CA2660605C (en) 2016-05-17
WO2008017517A1 (en) 2008-02-14
JP2010500308A (ja) 2010-01-07
PT2476435T (pt) 2018-03-05
EP2476437A3 (en) 2014-01-01
EP2059256B1 (en) 2016-08-03
ES2657480T3 (es) 2018-03-05
EP2476436A2 (en) 2012-07-18
JP2015142578A (ja) 2015-08-06
EP2476435B1 (en) 2017-12-20
AU2007283731A1 (en) 2008-02-14
US20100303866A1 (en) 2010-12-02
DK2059256T3 (en) 2016-12-05
DK2476436T3 (en) 2018-02-05
US10662232B2 (en) 2020-05-26
CA2926004A1 (en) 2008-02-14
US9249202B2 (en) 2016-02-02
EP2476435A3 (en) 2014-01-01
ES2601432T3 (es) 2017-02-15
PL2059256T3 (pl) 2017-02-28
AU2007283731B2 (en) 2013-10-24
PL2476436T3 (pl) 2018-05-30
PT2059256T (pt) 2016-11-08
EP2476435A2 (en) 2012-07-18
JP5750600B2 (ja) 2015-07-22
EP2476436A3 (en) 2014-01-01
EP2476436A9 (en) 2014-07-23
US20240034759A1 (en) 2024-02-01
DK2476435T3 (en) 2018-03-05
EP2476437B1 (en) 2018-11-28
EP2059256A1 (en) 2009-05-20
CA2660605A1 (en) 2008-02-14
EP2476437A2 (en) 2012-07-18
ES2709176T3 (es) 2019-04-15

Similar Documents

Publication Publication Date Title
PL2476435T3 (pl) Peptydy immunogenne i ich zastosowanie w zaburzeniach immunologicznych
SI3620171T1 (sl) Protitelesa proti GM-CSF in uporabe zanje
SI2185552T1 (sl) Dipeptoidna predzdravila in njihova uporaba
DK1991564T3 (da) Virosomlignende vesikler omfattende gp41-afledte antigener
ATE523524T1 (de) Antikörper und immunkonjugate gegen tat226
EP1895838A4 (en) COMPOSITIONS AND METHODS
HRP20140344T1 (en) Fviii peptides and their use in tolerising haemophiliacs
FR2868881B1 (fr) Titre en anglais
DE602005020202D1 (de) Getrennter Steckverbinder und Verbindereinrichtung
EP1746104A4 (en) NEW SOLUBLE CD14-ANTIGEN
DE602006003063D1 (de) Tripeptid- und tetrapeptidsulfone
SI1858481T1 (sl) Oftalmološki sestavki in njihova uporaba
GB0615635D0 (en) Immunogenic proteins and uses thereof
EP1773386A4 (en) VACCINE COMPOSITIONS AND METHODS
ZA200801874B (en) Antigenic peptides and their use
FI20041641L (fi) Sovitelma silmänpainemittarissa
EP2046815A4 (en) INFLAMMATORY AND ANTIALLERGIC CYCLIC PEPTIDES
IL181228A0 (en) Vlp-antigen conjugates and their uses as vaccines
DE602005015944D1 (de) Entspannungsstuhl
ITFI20060316A1 (it) Telecomandi in busvie e tranvie
ITGE20040086A1 (it) Valvole in sincronia
ZA200701667B (en) VLP-antigen conjugates and their use as vaccines
SE0400349L (sv) Anordning i samband med golf
SE0400151D0 (sv) Naturmedel med smärtlindrande egenskap
EE200900067A (et) Mutatsioonid inimese UBIAD1-s